Merck Will Not Pay Ranbaxy $100 Million For Anti-Infectives

This story has been bumping around in the online papers in India since Sunday night — but I’ve been waiting, for Whitehouse Station to confirm it, before running it:

. . . .The spokesperson for MSD Pharmaceuticals confirmed the development. “I can only confirm that research partnership has ended, but I cannot tell the reasons for it. . . .”

The billionaire brothers who founded Ranbaxy sold their stakes in the days after this deal was signed in 2008. Thus, it is at least possible that the subtle “pay to delay” side-effects — flowing from this deal — were considered by Merck to be no longer operative. And so, it was terminated.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s